Search results
18 cze 2018 · REAL-CAD (Randomized Evaluation of Aggressive or Moderate Lipid Lowering Therapy With Pitavastatin in Coronary Artery Disease) is currently the largest randomized trial to compare high-dose and low-dose statin therapy. It was also the first such trial performed in Asia.
The present subanalysis of the REAL-CAD study indicate that persistent inflammation is substantially associated with poor outcomes even in Japanese CCS patients taking pitavastatin, although the levels of hs-CRP in this population are relatively low.
8 maj 2018 · High-Dose Versus Low-Dose Pitavastatin in Japanese Patients With Stable Coronary Artery Disease (REAL-CAD): A Randomized Superiority Trial Circulation . 2018 May 8;137(19):1997-2009. doi: 10.1161/CIRCULATIONAHA.117.032615.
REAL-CAD is a prospective, multicenter, randomized, open-label, blinded-endpoint, physician-initiated phase 4 trial in Japan. The study will recruit up to 12,600 patients with stable CAD. Patients are assigned to re-ceive either pitavastatin 1 mg/day or pitavastatin 4 mg/day.
This prespecified subanalysis of the REAL-CAD study aimed to assess the prognostic effect of the persistent low-grade inflammation represented by high-sensitivity C-reactive protein (hs-CRP) in CCS patients.
18 cze 2018 · Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet . 2004; 364 :685–696. doi: 10.1016/S0140-6736(04)16895-5.
The REAL-CAD trial, a randomized controlled study, compared high-dose pitavastatin therapy with low-dose therapy in approximately 13,000 Japanese patients with stable CAD, demonstrating that high-dose statin therapy effectively and safely reduced major adverse cardiovascular events (MACEs). In this study, Kamiya et al. performed a posthoc
